Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

What is in Trump’s new 'gold card' website? Why is Couche-Tard divesting US stores for Seven & I deal? How is Starbucks' open-bathroom policy affecting sales? What caused Chime to price IPO above expectations? How will Trump's unilateral tariffs impact trade partners? Why did UNFI cyberattack disrupt Whole Foods supply? How did JPMorgan CEO Dimon warn on economy?

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

benzinga.com/analyst-stock-ratings/downgrades/25/06/45869551/keros-therapeutics-quiet-near-term-outlook-overshadows-pipeline-potential-analys

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18.
Zemansky noted that Keros has wrapped up its strategic review, with the board deciding to advance KER-065 for Duchenne…

This story appeared on benzinga.com, 2025-06-10 18:37:27.